Skip to main content

Share story

Security

Third-Party Breach at Polymarket Leads to $2.94M Crypto Theft

Third-Party Breach at Polymarket Leads to $2.94M Crypto Theft Image: Primary
Polymarket confirmed that a security breach at a third-party vendor allowed attackers to inject malicious code into its website, leading to the theft of funds from an undisclosed number of users, Security Affairs reported on June 26. The company said it has contained the incident and is contacting affected customers. It announced it will fully reimburse user losses, but technical details of the attack have not yet been disclosed. The attack first came to light when blockchain security researcher Specter spotted a phishing campaign that drained more than 11 Polymarket wallets holding PUSD. Experts estimated losses of $2.94 million and reported the attacker moved the stolen funds from Polygon to Ethereum and converted them into 1,893 ETH. Polymarket confirmed hackers stole funds from some users after attackers injected malicious code through a compromised third-party vendor.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Security Affairs and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.